On this page

Aim and selection

Microvascular decompression (MVD) is an operation intended to separate an offending blood vessel from the facial nerve when their relationship is judged relevant to hemifacial spasm. It addresses a possible underlying mechanism rather than temporarily reducing muscle activity. Clinical assessment and experienced image interpretation help determine suitability; incidental nerve-vessel contact alone is insufficient.1

Results for trigeminal neuralgia or another indication should not be substituted simply because the operation has the same name.

What a frequently cited result measures

The 2020 review pooled 39 studies involving 6,249 operated HFS patients. It reported spasm freedom in 5,652 patients (90.5%) at average last follow-up of about 1.25 years. The evidence was predominantly retrospective case series, with differences in selection, surgical technique and follow-up.2

This is a result in studied surgical populations, not a lifelong cure rate or a personal probability. It also does not show a randomized advantage over toxin. When a clinic quotes an outcome, ask what “success” meant, who was counted, how long patients were followed and whether incomplete follow-up was considered.

Risks and recovery

Reported complications include hearing loss, facial weakness and cerebrospinal-fluid leakage. Both temporary and persistent problems appear in the surgical literature. A consent discussion should relate the risks to the proposed operation and the team's experience. A general pooled result cannot replace that discussion.2

Spasm improvement may be delayed after surgery. The 2025 update describes variation in the time before relief becomes apparent. Recovery from an operation and the timing of spasm relief are separate issues; a universal number of days to resume normal activity would be misleading. Follow the treating team's advice on recovery and reassessment rather than interpreting every early contraction as failure.1

Residual symptoms and recurrence

Residual spasm means symptoms have not fully resolved. Recurrence means they return after initial success. The 2022 review examines the latter and reports recurrence in 64 of 1,105 patients across eight studies, with varying timing and follow-up. That fraction is not a fixed lifetime risk for all surgical patients.3

A 2024 review concerns 719 patients selected for reoperation across 17 studies. It separates complete from overall relief and reports persistent facial and hearing problems after revision. These selected patients cannot stand in for all first operations.4

Questions for the surgical team

Ask why the findings support MVD for this condition, what outcome is realistic to discuss, how follow-up handles delayed relief, and how complications or returning symptoms are assessed. Request the team's definitions and experience rather than a guarantee.

References

  1. Jesuthasan A, Natalwala A, Davagnanam I, Saifee T, Zrinzo L. J Neurol. 2025;272:502. doi:10.1007/s00415-025-13220-y. Source ↩
  2. Holste K, Sahyouni R, Teton Z, Chan AY, Englot DJ, Rolston JD. World Neurosurg. 2020;139:e383–e390. doi:10.1016/j.wneu.2020.04.001. Source ↩
  3. Menna G, Battistelli M, Rapisarda A, Izzo A, D’Ercole M, Olivi A, Montano N. Brain Sci. 2022;12(5):583. doi:10.3390/brainsci12050583. Source ↩
  4. Li Z, Zhang J, Wang N, Chen Y. Neurosurg Rev. 2024;47:804. doi:10.1007/s10143-024-03048-x. PubMed ↩